Rhumbline Advisers Summit Therapeutics Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 125,202 shares of SMMT stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

125,202

Previous 119,808 4.5%

Holding current value

$2.68 Million

Previous $2.62 Million 14.83%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$17.52 - $23.46 $94,502 - $126,543	5,394 Added 4.5%	125,202 $2.23 Million
Q3 2024 Nov 12, 2024	SELL	$6.89 - $31.93 $60,707 - $281,335	-8,811 Reduced 6.85%	119,808 $2.62 Million
Q2 2024 Aug 01, 2024	SELL	$2.39 - $10.92 $28,737 - $131,302	-12,024 Reduced 8.55%	128,619 $1 Million
Q1 2024 May 09, 2024	BUY	$2.55 - $5.07 $17,676 - $35,145	6,932 Added 5.18%	140,643 $582,000
Q4 2023 Feb 08, 2024	BUY	$1.67 - $2.83 $708 - $1,199	424 Added 0.32%	133,711 $348,000
Q3 2023 Nov 09, 2023	BUY	$1.54 - $2.42 $9,333 - $14,667	6,061 Added 4.76%	133,287 $249,000
Q2 2023 Aug 08, 2023	BUY	$1.32 - $2.81 $167,938 - $357,505	127,226 New	127,226 $319,000
Q2 2022 Aug 11, 2022	SELL	$0.92 - $2.38 $13,905 - $35,973	-15,115 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.0 - $3.45 $4,584 - $7,907	2,292 Added 17.87%	15,115 $37,000
Q4 2021 Feb 10, 2022	SELL	$2.45 - $5.64 $1,477 - $3,400	-603 Reduced 4.49%	12,823 $34,000
Q3 2021 Nov 12, 2021	BUY	$4.83 - $8.27 $4,385 - $7,509	908 Added 7.25%	13,426 $67,000
Q2 2021 Aug 05, 2021	BUY	$5.15 - $8.46 $64,467 - $105,902	12,518 New	12,518 $93,000

Others Institutions Holding SMMT

# of Institutions

233

Shares Held

84.5M

Call Options Held

1.97M

Put Options Held

2.86M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.3B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Summit Therapeutics Inc. Transaction History